Zydus Life Shares Soar 5% on Acquiring Assertio Holdings in US 

Shares of Zydus Lifesciences Ltd soared 5% on 14 May after it announced a major strategic acquisition by signing a definitive agreement to acquire Assertio Holdings in an all-cash transaction valued at nearly $166.4 million (around Rs 1,600 crore). 

Through its subsidiary, Zydus Worldwide DMCC, the company will purchase all outstanding shares of Assertio at $23.50 per share via a tender offer followed by a merger process. The deal is expected to close in FY27 after regulatory approvals and shareholder acceptance.

The acquisition significantly strengthens Zydus’ presence in the US specialty pharmaceutical market, particularly in oncology supportive care. 

Assertio’s portfolio is led by Rolvedon (eflapegrastim-xnst), a long-acting G-CSF therapy used to lower infection risks in cancer patients receiving chemotherapy. The treatment competes with Neulasta and its biosimilars while offering advantages such as lower injection-site reactions and broader insurance accessibility.

Assertio currently operates across more than 170 community oncology accounts in the United States, giving Zydus immediate access to an established specialty sales and distribution network. Instead of building a commercial oncology platform from the ground up, Zydus gains ready-made infrastructure that can support future specialty and biologic launches.

Managing Director Sharvil Patel described the acquisition as a key milestone in expanding the company’s differentiated global specialty business. Over the past few months, Zydus has also increased its focus on high-value oncology and specialty products through licensing and commercialization initiatives in the US market, highlighting a broader shift away from traditional generics toward complex therapies and biologics.

The transaction also follows a competitive acquisition process, where Assertio’s board selected Zydus’ proposal over previous merger agreements because of its stronger valuation and financing certainty. Once completed, Assertio will be delisted from Nasdaq, further integrating its operations into Zydus’ growing global specialty business.

At 12:41 pm, the shares of Zydus Lifesciences were trading 5.50% higher at Rs 990.90 on NSE.

Ready to invest like a pro? Tradz by EquityPandit app equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz by EquityPandit app and gain access to daily stock lists and insightful market analysis and much more!

The post Zydus Life Shares Soar 5% on Acquiring Assertio Holdings in US  appeared first on Equitypandit.